Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus

Vaudaux, Pierre; Gjinovci, Asllan; Bento, Manuela; Li, Dongmei; Schrenzel, Jacques; Lew, Daniel Pablo

doi:10.1128/AAC.49.9.3789-3793.2005

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus
Authors		Vaudaux, Pierre Gjinovci, Asllan Bento, Manuela Li, Dongmei Schrenzel, Jacques Lew, Daniel Pablo
Published in		Antimicrobial Agents and Chemotherapy. 2005, vol. 49, no. 9, p. 3789-3793
Abstract		The therapeutic activity of ceftobiprole medocaril, the water-soluble prodrug of ceftobiprole, was compared to that of vancomycin in a rat tissue cage model of chronic methicillin-resistant Staphylococcus aureus (MRSA) foreign-body infection. The MICs and MBCs of ceftobiprole and vancomycin in Mueller-Hinton broth for strain MRGR3 were 1 and 4 and 1 and 2 microg/ml, respectively. In vitro elimination rates of strain MRGR3 of 4 and 8 microg/ml of ceftobiprole or vancomycin were equivalent. After 2 weeks of infection, mean +/- standard error of the mean viable counts of strain MRGR3 were 6.83 +/- 0.11 log CFU/ml of tissue cage fluid (n = 87). High-dose regimens of ceftobiprole medocaril (equivalent to 150 mg/kg of ceftobiprole) or 50 mg/kg vancomycin produced nearly identical average peak and trough levels of ceftobiprole and vancomycin in tissue cage fluid, which exceeded the MBC of either antibiotic towards strain MRGR3 for > or =75% of each dosing interval. After 7 days of therapy with ceftobiprole medocaril or vancomycin, average counts of MRGR3 decreased significantly (P < 0.02) by 0.68 +/- 0.28 (n = 29) and 0.88 +/- 0.22 (n = 28) log CFU/ml of tissue cage fluid, respectively, compared with cages of untreated animals, but were not significantly different from each other. No resistant mutants were detected on ceftobiprole-supplemented agar following therapy with this cephalosporin. The in vivo activity of ceftobiprole medocaril against chronic MRSA foreign-body infections was equivalent to that of vancomycin and did not lead to the emergence of resistant subpopulations.
Keywords		Animals — Cephalosporins/pharmacokinetics/pharmacology/ therapeutic use — Foreign Bodies/ complications — Methicillin Resistance — Microbial Sensitivity Tests — Mutation/genetics — Rats — Rats, Wistar — Staphylococcal Infections/ drug therapy/ etiology — Staphylococcus aureus/drug effects/genetics — Vancomycin/therapeutic use
Identifiers		DOI: 10.1128/AAC.49.9.3789-3793.2005 PMID: 16127054
Full text		Article - Limited access to UNIGE Other version: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1195398/pdf/0223-05.pdf
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine
Citation (ISO format)		VAUDAUX, Pierre et al. Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. In: Antimicrobial Agents and Chemotherapy, 2005, vol. 49, n° 9, p. 3789-3793. doi: 10.1128/AAC.49.9.3789-3793.2005 https://archive-ouverte.unige.ch/unige:7652